A unidirectional porous beta-tricalcium phosphate material (Affinos®) for reconstruction of bony defects after excision of fibular bone for spinal surgery graft

• Published in: Journal of clinical neuroscience Vol. 66; pp. 71 - 76
• Main Authors: Noguchi, Hiroshi, Funayama, Toru, Koda, Masao, Iijima, Yasushi, Kumagai, Hiroshi, Ishikawa, Tetsuhiro, Aiba, Atsuomi, Abe, Tetsuya, Nagashima, Katsuya, Miura, Kousei, Izawa, Shigeo, Maki, Satoshi, Furuya, Takeo, Yamazaki, Masashi
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01.08.2019
• Subjects: Bone graft donor site; Bone remodeling; Regeneration of fibula; Spinal fusion surgery; β-tricalcium phosphate; Regeneration of fibula; Spinal fusion surgery; β-tricalcium phosphate; Bone remodeling; Bone graft donor site
• ISSN: 0967-5868; 1532-2653; 1532-2653
• DOI: 10.1016/j.jocn.2019.05.021

•Bone regeneration induced by Affinos® or OSferion® in fibula defects was compared.•Implanted β-TCP can promote repair of bone defects to regenerate fibula bone.•Fibula continuity for the Affinos® and OSferion® groups did not differ significantly.•Affinos® was absorbed more slowly than OSferion®.•The fibula defect filling ratio was higher for Affinos® than for OSferion®. The aim of this study was to elucidate the bone regeneration-inducing capability of Affinos®, a newly developed, high-porosity unidirectional porous β-TCP artificial bone. We compared the ability of Affinos® and OSferion®, a commercially available β-TCP product, to induce bone regeneration following implantation into bony defects left after fibula harvesting for spinal fusion surgery. Study subjects underwent surgery to harvest non-vascularized fibula grafts for spinal fusion surgery and were implanted with either Affinos® (19 patients) or OSferion® (15 patients, control group) at the defect site. The minimal and mean follow up periods were 6 and 11 months after surgery, respectively. X-rays of the lower leg taken 1–2 weeks after surgery and at the final follow-up visit were used to evaluate fibular-β-TCP continuity and fibula defect filling ratio. There was no significant difference in radiographic continuity in the fibula between the two groups. The fibula defect filling ratio for the Affinos® group decreased from 0.94 ± 0.17 at 1–2 weeks to 0.77 ± 0.14 at 10 months. For the OSferion® control group, the fibula defect filling ratio decreased from 0.94 ± 0.14 at 1–2 weeks to 0.52 ± 0.27 at final follow-up. The Affinos® group showed a significantly higher fibula defect filling ratio compared to that for the OSferion® group (p = 0.003). These results indicate that Affinos® has slow absorption rates and significant defect filling activity compared with OSferion®. Thus, Affinos® could be a suitable substitute to fill bony defects induced by fibula harvesting for spinal reconstruction surgery.